Sequenom Announces Additional, Positive Results for Down Syndrome Test at Analyst Briefing

Sequenom, Inc. (NASDAQ: SQNM), a leading provider of genetic-analysis and molecular diagnostic solutions, announced additional, positive results from screening studies using the Company’s noninvasive circulating cell-free fetal (ccff) nucleic acid SEQureDx™ Technology, which enables the detection of fetal aneuploidy, including Down syndrome from maternal blood, at its Analyst Briefing in New York City. Among the data presented, Sequenom’s test demonstrated complete concordance with clinical results (no false positives and no false negatives) in both first and second trimester samples (over 200 samples announced today and in excess of 400 prospective samples to-date). Sequenom executives were joined by a panel of leading scientists and clinicians to discuss these study results and updates in the development of noninvasive prenatal diagnostics.

Published: 24 September 2008
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News  
Read more: Sequenom Inc ( SQNM )

Amorfix sets up vCJD blood screening assay in UK and begins to test blood donor samples

Amorfix Life Sciences, a company focused on treatments and diagnostics for brain wasting diseases, announced today it has set up the EP-vCJD(TM) assay system in the Prion Laboratory at the British National Institute for Biological Standards and Control (NIBSC) and has begun to test fresh human blood samples as part of the ongoing assay validation process announced earlier this year.

"NIBSC and the UK National Blood Service have been exceedingly helpful in establishing the performance of the EP-vCJD(TM) assay on routine samples from blood donors," said Dr. George Adams, Chief Executive Officer of Amorfix. "We expect to finish this alpha-site testing program in a month and demonstrate the required specificity for the assay."

Published: 23 September 2008
Written by Editor
TSX   Healthcare   Project Updates   Up on News  
Read more: Amorfix Life Sciences ( AMF )